LOGIN  |  REGISTER
Astria Therapeutics
Chimerix

Bright Health to Host Second Quarter 2023 Earnings Conference Call on August 9, 2023

July 17, 2023 | Last Trade: US$4.66 0.42 -8.27

MINNEAPOLIS / Jul 17, 2023 / Business Wire / Bright Health Group, Inc. ("Bright Health") (NYSE: BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today announced it will report Second Quarter financial results before the financial markets open on Wednesday, August 9, 2023, followed by a conference call at 8:00 AM Eastern Time.

To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call.

A webcast of the earnings call may also be accessed via Bright Health’s Investor Relations page at investors.brighthealthgroup.com. The company suggests participants for the conference call dial in at least 15 minutes in advance of the call. A recording of the earnings call and presentation will be available on Bright Health’s Investor Relations page following the call.

About Bright Health Group

Bright Health Group is a technology enabled, value-driven healthcare company that organizes and operates networks of affiliate care providers to be successful at managing population risk. We focus on serving aging and underserved consumers that have unmet clinical needs through our Fully Aligned Care Model in Florida, Texas and California, some of the largest markets in healthcare where 26% of the U.S. aging population call home. We believe everyone should have access to personal, affordable, and high-quality healthcare. Our mission is to Make healthcare right. Together. For more information, visit www.brighthealthgroup.com.

Viking Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page